Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF) Sets New 12-Month Low at $51.60

Recordati Industria Chimica e Farmaceutica S.p.A. (OTCMKTS:RCDTFGet Free Report)’s share price reached a new 52-week low during mid-day trading on Friday . The company traded as low as $51.60 and last traded at $51.60, with a volume of 0 shares trading hands. The stock had previously closed at $51.60.

Recordati Industria Chimica e Farmaceutica Price Performance

The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.86 and a current ratio of 1.28. The company’s 50-day moving average price is $51.60 and its 200 day moving average price is $50.12.

Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTFGet Free Report) last released its quarterly earnings results on Thursday, May 9th. The company reported $0.85 earnings per share for the quarter. The business had revenue of $659.94 million for the quarter. Recordati Industria Chimica e Farmaceutica had a net margin of 18.51% and a return on equity of 31.80%. Sell-side analysts forecast that Recordati Industria Chimica e Farmaceutica S.p.A. will post 2.81 EPS for the current fiscal year.

Recordati Industria Chimica e Farmaceutica Company Profile

(Get Free Report)

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis.

See Also

Receive News & Ratings for Recordati Industria Chimica e Farmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recordati Industria Chimica e Farmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.